Stock TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Teva Pharmaceutical Industries Ltd (ADR) Share Price Nasdaq

Equities

US8816242098

Pharmaceuticals

Financials

Sales 2024 * 15.86B 1,266B Sales 2025 * 16.4B 1,309B Capitalization 15.83B 1,264B
Net income 2024 * 1.54B 123B Net income 2025 * 1.44B 115B EV / Sales 2024 * 1.93 x
Net Debt 2024 * 14.82B 1,182B Net Debt 2025 * 12.25B 978B EV / Sales 2025 * 1.71 x
P/E ratio 2024 *
11.2 x
P/E ratio 2025 *
10.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.71%
More Fundamentals * Assessed data

Chart Teva Pharmaceutical Industries Ltd (ADR)

Dynamic Chart

Latest news about Teva Pharmaceutical Industries Ltd (ADR)

FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications MT
Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent MT
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) CI
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis MT
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment DJ
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints MT
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China CI
More news

Latest transcript on Teva Pharmaceutical Industries Ltd (ADR)

Logo Teva Pharmaceutical Industries Ltd (ADR)
Teva Pharmaceutical Industries Limited, Q4 2023 Earnings Call, Jan 31, 2024
More transcripts

Analyst Recommendations on Teva Pharmaceutical Industries Ltd (ADR)

JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11 MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12 MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating MT
More recommendations

Press releases Teva Pharmaceutical Industries Ltd (ADR)

Alvotech - U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-FreeInterchangeable Biosimilar to Humira AQ
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) BU
Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO Tablets AQ
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) BU
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) AQ
More press releases

News in other languages on Teva Pharmaceutical Industries Ltd (ADR)

HINTERGRUND/FTC knöpft sich Patentanmeldungen für Arzneimittel vor
FDA rechaza aprobación de inyección de Viatris para la esclerosis múltiple
Alcoa : Berkshire Hathaway, Teva... les valeurs à suivre aujourd'hui à Wall Street -
Teva Pharmaceutical Industries : attendu en hausse après l'approbation du Simlandi par la FDA
Après 37 ans à la barre, Nicolas de Tavernost va quitter la direction de M6
More news

Managers and Directors - Teva Pharmaceutical Industries Ltd (ADR)

Managers TitleAgeSince
Richard Francis CEO
 Chief Executive Officer 55 31/12/22
Eli Kalif DFI
 Director of Finance/CFO 51 21/12/19
Eric Hughes CTO
 Chief Tech/Sci/R&D Officer - 31/07/22
Members of the board TitleAgeSince
Gerald Lieberman BRD
 Director/Board Member 77 31/08/15
Janet Vergis BRD
 Director/Board Member 60 08/06/20
Sol Barer CHM
 Chairman 76 31/12/14
More insiders

Company Profile

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
Calendar
08/05/2024 - Q1 2024 Earnings Release
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+33.25% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+28.59% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.55% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.16% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.36% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.81% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-3.69% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. Stock